1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,080 | 1,210 | 14:08 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.07. | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 24.06. | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 16.06. | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 19.05. | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| GENENTA SCIENCE Aktie jetzt für 0€ handeln | |||||
| 27.04. | Genenta: €6 Million Deal For Sophia High Tech Marks Entry Into Aerospace And Defense With Majority Stake Path | 2 | pulse2.com | ||
| 23.04. | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 23.04. | Genenta to buy majority stake in aerospace parts maker for €6M | 4 | Seeking Alpha | ||
| 23.04. | GENENTA SCIENCE SPA: Genenta signs Definitive Agreements with Sophia High Tech | 460 | GlobeNewswire (Europe) | MILAN,Italy, April 23, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and... ► Artikel lesen | |
| 14.04. | Genenta Science S.p.A. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 27.03. | GENENTA SCIENCE SPA: Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs | 845 | GlobeNewswire (Europe) | MILAN, March 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian... ► Artikel lesen | |
| 24.03. | GENENTA SCIENCE SPA: Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini | 369 | GlobeNewswire (Europe) | MILAN, March 24, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian... ► Artikel lesen | |
| 13.03. | GENENTA SCIENCE SPA: Genenta, Evolving into Saentra Forge, Announces CEO's Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University | 566 | GlobeNewswire (Europe) | MILAN, March 13, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge (Nasdaq: SAEN)1, a strategic industrial consolidator focused on biotech, defense, aerospace... ► Artikel lesen | |
| 28.02. | Genenta Science SPA (GNTA) Shifting from Biotech to Defense Business | 4 | Insider Monkey | ||
| 27.02. | GENENTA SCIENCE SPA: Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform | 624 | GlobeNewswire (Europe) | MILAN, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) in transformation to Saentra Forge (Nasdaq: SAEN), a strategic industrial consolidator focused on biotech, defense, aerospace... ► Artikel lesen | |
| 27.01. | Micro-Cap Genenta Stock Reacts To Its Big Pivot From Biotech To Defense Investments | 4 | Benzinga.com | ||
| 27.01. | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 27.01. | GENENTA SCIENCE SPA: Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator | 500 | GlobeNewswire (Europe) | Building on Biotech Heritage, Expanding into Defense and National Security Through Industrial Integrations of Privately Held Specialized Italian CompaniesATC - a Defense-Sector Company: First Industrial... ► Artikel lesen | |
| 19.12.25 | GENENTA SCIENCE SPA: Genenta Science Provides Update on CEO Ownership | 378 | GlobeNewswire (Europe) | MILAN and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage gene-therapy company developing hematopoietic stem-cell-based immunotherapies for solid tumors... ► Artikel lesen | |
| 24.11.25 | GENENTA SCIENCE SPA: Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial | 409 | GlobeNewswire (Europe) | MILAN, Italy and NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage biotechnology company developing a cell-based platform for targeted delivery of therapeutic... ► Artikel lesen | |
| 24.10.25 | GENENTA SCIENCE SPA: Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production | 1.698 | GlobeNewswire (Europe) | MILAN, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 3,680 | -25,54 % | Evotec-Aktie: Geht die Seitwärtsbewegung weiter? | Die Evotec-Aktie bewegt sich seit mehreren Wochen in einer engen Handelsspanne um die Marke von 5 €. Weder den Bullen noch den Bären ist bislang ein nachhaltiger Ausbruch gelungen. Am Mittwoch notiert... ► Artikel lesen | |
| BB BIOTECH | 54,10 | -0,92 % | BB Biotech hält dagegen | Die Schweizer Beteiligungsgesellschaft im Biotech-Sektor generiert mit dem Break bei 50 CHF ein neues Kaufsignal und stellt sich gegen den Gesamtmarkt der letzten 2 Tage. Aktueller Abschlag je Aktie... ► Artikel lesen | |
| MODERNA | 58,70 | -0,25 % | Moderna-Aktie mit -11% - Einstieg nach der Korrektur? | Die Moderna-Aktie hat nach ihrer beeindruckenden Rallye zuletzt einen Dämpfer hinnehmen müssen und am gestrigen Handelstag rund -11% an Wert verloren. Damit rückt die Aktie nach dem starken Kursanstieg... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 44,830 | +0,82 % | 3 Reasons to Buy CRISPR Therapeutics Stock | ||
| NANOREPRO | 2,100 | -2,78 % | NanoRepro: Attraktive Positionierung | Nach Darstellung der Analysten Matthias Greiffenberger und Cosmin Filker von GBC hat die NanoRepro AG die bisherige europäische Vertriebs- und Lizenzvereinbarung für das FiberSense-CGM-System in eine... ► Artikel lesen | |
| AAP IMPLANTATE | 1,550 | -2,52 % | EQS-HV: aap Implantate AG: Bekanntmachung der Einberufung zur Hauptversammlung am 23.06.2026 in Berlin mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG | EQS-News: aap Implantate AG
/ Bekanntmachung der Einberufung zur Hauptversammlung
aap Implantate AG: Bekanntmachung der Einberufung zur Hauptversammlung am 23.06.2026 in Berlin... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,998 | 0,00 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| INFLARX | 1,758 | -2,60 % | BRANDMELDUNG bei InflaRx NV: Könnte die Aktie jetzt komplett durchstarten? - Meine klare Einschätzung dazu | ||
| INTELLIA THERAPEUTICS | 11,720 | +2,45 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published... ► Artikel lesen | |
| TEMPUS AI | 48,340 | -1,58 % | Freedom Capital Initiates Coverage of Tempus AI, Inc. (TEM) | ||
| EDITAS MEDICINE | 2,640 | -4,69 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 52,02 | +0,31 % | BioMarin Pharmaceutical Inc.: U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO (vosoritide) for Children With Achondroplasia | Application based on long-term safety and efficacy data from three ongoing studies, including adult height and additional clinical outcomes beyond linear growth... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,906 | -1,20 % | Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association | ||
| EVONEXT | 2,140 | 0,00 % | EvoNext Holdings SA: EvoNext shareholders approve all motions proposed by the Board at the Annual General Meeting 2026 | EvoNext Holdings SA
/ Key word(s): AGMEGM
EvoNext shareholders approve all motions proposed by the Board at the Annual General Meeting 2026
20.05.2026 / 17:01 CET/CEST
PRESS... ► Artikel lesen | |
| IBIO | 1,306 | +1,48 % | iBio, Inc.: iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study | Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach When combined with semaglutide, IBIO-610 drove... ► Artikel lesen |
GENENTA SCIENCE SPA ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,100 Euro und damit -8,33 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENENTA SCIENCE SPA ADR finden Sie auf Wallstreet Online.